肺癌免疫检查点抑制剂相关心脏毒性研究进展  

Research progress on cardiotoxicity related to immune checkpoint inhibitors in lung cancer

作　　者：曹文莉 韩森[1] 方健[1] Cao Wenli;Han Sen;Fang Jian(Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Peking University Cancer Hospital&Institute,Beijing 100142,China)

机构地区：[1]北京大学肿瘤医院、暨北京市肿瘤防治研究所、恶性肿瘤发病机制及转化研究教育部重点实验室,北京100142

出　　处：《中华心力衰竭和心肌病杂志（中英文）》2024年第1期78-83,共6页Chinese Journal of Heart Failure and Cardiomyopathy

基　　金：北京市医院管理中心培育计划(PX2023040)。

摘　　要：免疫检查点抑制剂(ICIs)是癌症治疗领域的重要进展,在改善患者预后方面取得了显著成就。肺癌作为最常见的恶性肿瘤之一,ICIs已经在肺癌患者中广泛应用。然而,患者在免疫治疗获益的同时也伴随着一系列相关的不良反应,即免疫相关不良反应(irAEs)。在肺癌的免疫治疗中,ICIs相关心脏毒性受到越来越多的关注,包括心肌炎、心包炎、心律失常等。虽然发生率较低,但严重程度较高,甚至危及生命。因此,对肺癌患者在接受免疫治疗中可能出现的心脏毒性进行早期识别、监测和治疗显得尤为重要。本文通过对这一领域的前沿知识进行综述,为临床医生提供更全面的了解和有效的临床管理策略,从而最大程度地确保肺癌患者在接受免疫治疗时的安全性。Immune checkpoint inhibitors(ICIs)are an important advance in the field of cancer treatment,and have made significant achievements in improving patient prognosis.ICIs has also been widely used in lung cancer patients which is one of the most common malignant tumors.However,patients benefit from immunotherapy with a series of related adverse reactions,namely immune related adverse reactions(irAEs).In the immunotherapy of lung cancer,ICIs-related cardiac toxicity has received more and more attention,including myocarditis,pericarditis,arrhythmia,etc.Although the incidence is low,the severity is high,and even life-threatening.Therefore,it is particularly important to early identify,monitor,and treat the potential cardiac toxicity in lung cancer patients receiving immunotherapy.This article reviews the frontier knowledge in this field to provide clinicians with a more comprehensive understanding and effective clinical management strategies,so as to ensure the safety of lung cancer patients receiving immunotherapy to the greatest extent.

关 键 词：肺癌 免疫检查点抑制剂 心脏毒性 

分 类 号：R734.2[医药卫生—肿瘤]